Brief: Neurosense Therapeutics Achieves Primary Endpoint In Phase 2B ALS Study
29/06/2026 15:34
BRIEF-Neurosense Therapeutics Achieves Primary Endpoint In Phase 2B ALS Study June 29 (Reuters) - Neurosense Therapeutics Ltd NRSN.O:
NEUROSENSE ACHIEVES PRIMARY ENDPOINT IN PHASE 2B ALS STUDY WITH STATISTICALLY SIGNIFICANT REDUCTION OF TDP-43, THE DEFINING PATHOLOGICAL HALLMARK OF ALS
NEUROSENSE THERAPEUTICS - PRIMEC SHOWS FAVORABLE SAFETY PROFILE WITH NO NEW SAFETY SIGNALS OVER 18 MONTHS
NEUROSENSE THERAPEUTICS - PRIMEC SHOWS SIGNIFICANT TDP-43 REDUCTION AT DAY 180 AND DAY 540 IN PHASE 2B ALS STUDY
Source text: ID:nPn6VBrgVa
Further company coverage: NRSN.O